Muller & Phipps (India) Ltd
Incorporated in 1917, Muller & Phipps
(India) Ltd marketing of its own brands
in the Dental and Skin Care segments[1]
- Market Cap ₹ 13.9 Cr.
- Current Price ₹ 223
- High / Low ₹ 377 / 188
- Stock P/E
- Book Value ₹ -33.0
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.24% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 3.47 | 3.40 | 3.13 | 3.74 | 3.61 | 3.97 | 3.67 | 3.91 | 4.14 | 5.80 | 5.63 | |
| 4.88 | 3.59 | 3.40 | 3.10 | 3.36 | 3.50 | 3.72 | 3.50 | 3.86 | 4.16 | 6.76 | 6.85 | |
| Operating Profit | -0.38 | -0.12 | 0.00 | 0.03 | 0.38 | 0.11 | 0.25 | 0.17 | 0.05 | -0.02 | -0.96 | -1.22 |
| OPM % | -8.44% | -3.46% | 0.00% | 0.96% | 10.16% | 3.05% | 6.30% | 4.63% | 1.28% | -0.48% | -16.55% | -21.67% |
| 1.14 | 0.38 | 0.30 | 0.18 | 0.08 | 0.38 | 1.61 | 0.38 | 0.26 | 0.83 | 0.28 | 1.28 | |
| Interest | 0.31 | 0.31 | 0.24 | 0.24 | 0.21 | 0.14 | 0.12 | 0.10 | 0.09 | 0.07 | 0.06 | 0.08 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 0.44 | -0.06 | 0.05 | -0.04 | 0.24 | 0.34 | 1.73 | 0.44 | 0.21 | 0.73 | -0.75 | -0.03 |
| Tax % | 0.00% | 0.00% | 20.00% | 0.00% | 20.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.44 | -0.06 | 0.03 | -0.04 | 0.19 | 0.34 | 1.73 | 0.44 | 0.21 | 0.73 | -0.75 | -0.03 | |
| EPS in Rs | 7.04 | -0.96 | 0.48 | -0.64 | 3.04 | 5.44 | 27.68 | 7.04 | 3.36 | 11.68 | -12.00 | -0.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 7% |
| 3 Years: | 13% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 96% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 20% |
| 3 Years: | 20% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| Reserves | -5.52 | -5.58 | -5.52 | -5.55 | -5.35 | -5.00 | -3.30 | -2.87 | -2.66 | -1.93 | -2.70 | -2.69 |
| 1.90 | 1.89 | 1.89 | 1.89 | 2.04 | 1.90 | 1.62 | 1.34 | 1.06 | 0.79 | 0.84 | 0.76 | |
| 7.66 | 7.55 | 7.60 | 7.51 | 7.50 | 7.36 | 5.73 | 5.74 | 5.95 | 5.77 | 6.95 | 7.19 | |
| Total Liabilities | 4.67 | 4.49 | 4.60 | 4.48 | 4.82 | 4.89 | 4.68 | 4.84 | 4.98 | 5.26 | 5.72 | 5.89 |
| 0.08 | 0.07 | 0.04 | 0.05 | 0.04 | 0.07 | 0.07 | 0.06 | 0.05 | 0.06 | 0.06 | 0.05 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 4.58 | 4.41 | 4.55 | 4.42 | 4.77 | 4.81 | 4.60 | 4.77 | 4.92 | 5.19 | 5.65 | 5.83 | |
| Total Assets | 4.67 | 4.49 | 4.60 | 4.48 | 4.82 | 4.89 | 4.68 | 4.84 | 4.98 | 5.26 | 5.72 | 5.89 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.03 | 0.07 | 0.16 | -0.01 | 0.15 | 2.16 | 0.11 | 0.21 | 0.73 | -0.42 | ||
| 0.00 | 0.00 | 0.01 | -0.02 | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | -0.02 | -0.01 | ||
| -0.50 | -0.05 | -0.04 | -0.07 | 0.10 | -0.26 | -1.76 | -0.38 | -0.34 | -0.32 | 0.05 | ||
| Net Cash Flow | 0.00 | -0.01 | 0.04 | 0.07 | 0.09 | -0.14 | 0.39 | -0.27 | -0.13 | 0.39 | -0.38 | |
| Free Cash Flow | 0.51 | 0.03 | 0.08 | 0.14 | -0.01 | 0.12 | 2.15 | 0.11 | 0.21 | 0.71 | -0.43 | |
| CFO/OP | -134% | -25% | 567% | 8% | 382% | 600% | 141% | 480% | -3,800% | 44% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51.10 | 50.49 | 59.04 | 40.81 | 40.01 | 30.33 | 45.05 | 71.61 | 88.68 | 73.18 | 110.76 | 115.40 |
| Inventory Days | 3.13 | 2.04 | 8.44 | 13.42 | 16.17 | 34.30 | 26.55 | 45.03 | 36.08 | 32.09 | 16.15 | 29.80 |
| Days Payable | 458.99 | 519.97 | 525.35 | 641.43 | 542.88 | 575.67 | 455.70 | 502.47 | 481.72 | 58.16 | 119.51 | 134.08 |
| Cash Conversion Cycle | -404.76 | -467.44 | -457.86 | -587.20 | -486.70 | -511.04 | -384.10 | -385.83 | -356.96 | 47.10 | 7.40 | 11.11 |
| Working Capital Days | -463.96 | -622.71 | -421.90 | -473.45 | -387.45 | -386.23 | -184.80 | -172.06 | -152.16 | -140.18 | -117.68 | -130.96 |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cosmetics / Toiletries Sales Value Rupees |
|
|||||||||
| Medicated Preparations Sales Value Rupees |
||||||||||
| Number of Regional Offices and Depots Count |
||||||||||
| Revenue Concentration (Top 10 Clients) Percentage |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Audited Financial Results For The Quarter And Year Ended 31-03-2026 1d
-
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31-03-2026
1d - Board approved FY26 audited results; Mr. P.V. Mohan resigned as Whole-Time Director effective 31 May 2026.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Submitted FY26 secretarial compliance report; website technical snag noted, but overall compliance confirmed.
-
Board Meeting Intimation for Considering The Audited Financial Results (Standalone+ Consolidated) For The Quarter And Year Ended 31-03-2026
15 May - Board meeting on May 28, 2026 to consider audited financial statements for year and quarter ended March 31, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
MPIL is engaged in marketing of over-the-counter medical preparations and home care
products. It has developed a wide distribution set-up throughout the country, covering around 40,100 chemists, 65,700 General Stores, 82,450 Provisional /Kirana stores, and around
2345 Super Markets.